Biocon to transfer biosimilar business through ‘slump sale’
Shital Jibhe / 22 Aug 2017
Biocon will transfer the biosimilar business of the company by way of slump sale as ‘going concern’ to Biocon Biologics India, a step-down subsidiary of the company, subject to
Biocon will transfer the biosimilar business of the company by way of slump sale as ‘going concern’ to Biocon Biologics India, a step-down subsidiary of the company, subject to
Meanwhile, the stock, on Monday’s trade ended in the green, gaining 0.55% at Rs 328.80 per share on the BSE. The company has had a return on equity of 12.02% for the past three years. Its dividend payout was 12.05% over the past three years.
A biopharmaceutical company, Biocon focuses to reducing therapy costs of chronic diseases like autoimmune, diabetes, and cancer. As the latest update, its drug product facility for Trastuzumab and Pegfilgrastim was being re-inspected by the EMA Committee for Medicinal Products for Human Use (CHMP) last week.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.